KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) SEC Filings, Aug-Oct 2025

Form 144 notice by an insider of Kewaunee Scientific Corp (KEQU) discloses a proposed sale of 1,000 common shares through Fidelity Brokerage Services (Boston) with an aggregate market value of $42,720, and lists prior open-market sales by the same person totaling 5,000 shares across five transactions between September 18–29, 2025, generating gross proceeds shown for each trade. The 1,000 shares were acquired as a stock award on June 30, 2024 and were issued as compensation. The filer certifies they are not aware of undisclosed material adverse information about the issuer.

Thomas David Hull III, President, CEO and director of Kewaunee Scientific Corp (KEQU), reported two open-market sales of common stock on September 23-24, 2025. He sold 721 shares on 09/23/2025 at a weighted-average price shown as $44 and an additional 1,000 shares on 09/24/2025 at a weighted-average price shown as $43.62. After the September 23 trade his beneficial ownership was 42,573 shares and after the September 24 trade it was 41,573 shares. The form was signed by an attorney-in-fact on 09/24/2025. The filing includes a note that reported prices are weighted averages and that the filer will provide breakdowns on request.

Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.

Campbell John Jette, identified as a director of Kewaunee Scientific Corp (KEQU), filed an initial Section 16 Form 3 reporting the transaction date 09/10/2025. The filing states no securities are beneficially owned by the reporting person and includes a power of attorney (Exhibit 24) with the form signed by an attorney-in-fact on 09/11/2025. This is an initial ownership disclosure showing the director currently holds no reportable equity.

Kewaunee Scientific announced the appointment of Mr. Campbell to its Board and approved amended bylaws. Mr. Campbell brings extensive finance and restructuring experience from roles at Carl Marks Advisors and prior executive positions at Griffin LLC, PepsiCo and Frito-Lay, and is a certified public accountant with decades in public accounting and corporate finance. The Board determined he meets Nasdaq and SEC independence and financial literacy requirements and has named him to the Audit Committee.

The company said Mr. Campbell will be paid under the standard non-employee director program and will receive a pro-rated equity grant for fiscal 2026. The Board also amended Section 5.02 of the Bylaws to set the Board size at a minimum of five and maximum of nine directors, with the exact number fixed by Board resolution.

Kewaunee Scientific Corporation filed a current report to let investors know it has released financial results for the first quarter of its fiscal year 2026. The company states that these results were announced in a press release dated September 10, 2025, which is provided as Exhibit 99.1.

The report explains that this press release is being furnished, rather than filed, which limits how it is treated under securities laws. Kewaunee’s common stock continues to trade on the Nasdaq Global Market under the symbol KEQU.

Kewaunee Scientific Corporation reported the results of its Annual Meeting of Shareholders held on August 27, 2025. Shareholders re-elected Class III directors Margaret B. Pyle and Donald F. Shaw, with Pyle receiving 1,633,067 votes for and 189,229 withheld, and Shaw receiving 1,730,171 votes for and 92,125 withheld, along with 537,449 broker non-votes for each nominee.

Shareholders ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal 2026, with 2,356,636 votes for, 2,119 against, and 990 abstentions. On an advisory basis, shareholders approved the compensation of the named executive officers with 1,448,991 votes for, 103,177 against, 270,128 abstentions, and 537,449 non-votes.

In an advisory vote on the frequency of future say-on-pay votes, shareholders favored holding the vote every one year, with 1,512,884 votes for one year, 1,194 for two years, 306,985 for three years, 1,233 abstentions, and 537,449 non-votes. The company will include an annual non-binding advisory vote on executive compensation in its proxy materials consistent with this outcome and the Board’s recommendation.

Kewaunee Scientific Corporation filed a current report to let investors know when it will share its next results. The company announced that it plans to release its first quarter fiscal 2026 earnings on September 10, 2025. This update is provided through a press release that is attached to the report as an exhibit and incorporated by reference.

Kewaunee Scientific Corporation furnished an investor presentation and related script in connection with its virtual Annual Meeting of Shareholders held at 11:00 a.m. Eastern time on August 27, 2025. These materials, attached as Exhibits 99.1 and 99.2, are also available in the Investor Information section of the company’s website and a replay of the audio webcast of the meeting will remain accessible for about one year. The company uses non-GAAP financial measures in the presentation and provides reconciliations to comparable GAAP measures in the same location. The materials also include forward-looking statements, and the company points investors to its Form 10-K for the year ended April 30, 2025 and other SEC filings for a discussion of risk factors that could cause actual results to differ.